A 7-year-old girl from a rural village in Uttar Pradesh is brought by her mother with complaints of eye discharge and mild photophobia for the past 3 months. On examination, the child has bilateral upper tarsal follicles (>5 follicles), conjunctival injection, and no corneal involvement. A diagnosis of trachoma is suspected. According to WHO guidelines for trachoma elimination in endemic areas, which of the following is the most appropriate management for this child?

Explanation

## Management of Active Trachoma in Children: WHO Guidelines **Key Point:** For trachomatous inflammation-follicular (TF) in children <5 years in endemic areas, WHO recommends **single-dose azithromycin 20 mg/kg** as the first-line treatment. This approach maximizes compliance and is part of the SAFE strategy for trachoma elimination. ### WHO SAFE Strategy for Trachoma Elimination | Component | Intervention | Goal | |-----------|--------------|------| | **S** | **Surgery** | Correct trichiasis and entropion to prevent blindness | | **A** | **Antibiotics** | Treat active infection (*Chlamydia trachomatis*) | | **F** | **Facial cleanliness** | Reduce transmission, especially in children | | **E** | **Environmental improvement** | Improve water access and sanitation | ### Antibiotic Regimens for Trachoma | Regimen | Indication | Dosing | Advantage | |---------|-----------|--------|----------| | **Azithromycin (single-dose)** | TF in children <5 years, endemic areas | 20 mg/kg once | Excellent compliance, single visit | | **Azithromycin (weekly)** | TI in older children/adults | 20 mg/kg once weekly × 3 weeks | Treats active inflammation | | **Tetracycline ointment** | Alternative for active disease | 1% QID × 6 weeks | Topical option, less systemic absorption | | **Doxycycline** | Contraindicated | — | Causes dental staining in children <8 years | **High-Yield:** Single-dose azithromycin for TF in endemic areas is WHO-recommended because: 1. **Compliance:** One dose vs. 6-week course. 2. **Efficacy:** Microbiologically equivalent to 6-week tetracycline regimen. 3. **Population-level impact:** Reduces transmission in endemic settings. 4. **Safety:** Well-tolerated in children; no dental staining risk. ### Clinical Classification in This Case The child has: - Bilateral upper tarsal follicles (≥5) - No corneal involvement - Age <5 years (7 years, but still in pediatric category) - Chronic presentation (3 months) **→ Diagnosis: TF (Trachomatous Inflammation-Follicular)** ```mermaid flowchart TD A["Suspected Trachoma<br/>Child <5 years"]:::outcome --> B{"Classify by WHO<br/>grading"}:::decision B -->|"≥5 follicles on<br/>upper tarsus"| C["TF (Trachomatous<br/>Inflammation-Follicular)"]:::outcome B -->|"Intense inflammation<br/>obscuring vessels"| D["TI (Trachomatous<br/>Inflammation-Intense)"]:::outcome C --> E["Single-dose<br/>Azithromycin 20 mg/kg"]:::action D --> F["Azithromycin 20 mg/kg<br/>weekly × 3 weeks"]:::action E --> G["Microbiological cure<br/>+ compliance"]:::outcome F --> G ``` ### Why Single-Dose Azithromycin? 1. **Pharmacokinetics:** Azithromycin has a long tissue half-life (~68 hours) and concentrates in conjunctival tissue. 2. **Clinical trials:** Non-inferiority demonstrated vs. 6-week tetracycline in endemic trachoma. 3. **Compliance:** Single visit eliminates adherence barriers. 4. **Population strategy:** In endemic areas, mass drug administration with single-dose azithromycin reduces community transmission. **Clinical Pearl:** In older children and adults with **TI (intense inflammation)**, a 3-week course of weekly azithromycin (20 mg/kg once weekly) is preferred to address more severe inflammation. ### Adjunctive Measures - **Facial cleanliness:** Daily face washing to reduce transmission. - **Environmental:** Improve water access, sanitation. - **Screening:** Examine siblings and contacts. [cite:WHO Simplified Trachoma Grading System & Elimination Guidelines; Khurana Comprehensive Ophthalmology 6e Ch 5]